LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $115,361 | +203.9% | 81,816 | +223.3% | 0.00% | – |
| Q1 2023 | $37,959 | +5.8% | 25,306 | -17.5% | 0.00% | – |
| Q4 2022 | $35,875 | -97.3% | 30,662 | -94.3% | 0.00% | -100.0% |
| Q4 2021 | $1,325,000 | -9.5% | 540,824 | -6.9% | 0.00% | 0.0% |
| Q3 2021 | $1,464,000 | -60.9% | 580,788 | -55.8% | 0.00% | -62.5% |
| Q2 2021 | $3,747,000 | +27.1% | 1,314,567 | +4.8% | 0.01% | 0.0% |
| Q1 2021 | $2,948,000 | +206.1% | 1,254,531 | +129.3% | 0.01% | +166.7% |
| Q4 2020 | $963,000 | +388.8% | 547,215 | +160.6% | 0.00% | +200.0% |
| Q3 2020 | $197,000 | -31.1% | 210,005 | -36.2% | 0.00% | 0.0% |
| Q2 2020 | $286,000 | +111.9% | 328,941 | +102.3% | 0.00% | 0.0% |
| Q1 2020 | $135,000 | -57.1% | 162,633 | -54.0% | 0.00% | 0.0% |
| Q4 2019 | $315,000 | -3.4% | 353,705 | +6.2% | 0.00% | 0.0% |
| Q3 2019 | $326,000 | – | 333,095 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
| BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
| Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
| Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
| Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
| Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
| DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
| Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |